Avadel's narcolepsy drug Lumryz misses PDUFA date, still under review at FDA

Katherine Lewin

News Reporter

Avadel Pharmaceuticals is still waiting on an answer from the FDA on whether its once-nightly narcolepsy drug Lumryz will be approved to include the pediatric …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Avadel's narcolepsy drug Lumryz misses PDUFA date, still under review at FDA

Katherine Lewin

News Reporter

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Avadel's nar­colep­sy drug Lum­ryz miss­es PDU­FA date, still un­der re­view at FDA

Katherine Lewin

News Reporter

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Avadel's narcolepsy drug Lumryz misses PDUFA date, still under review at FDA

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya